One of the goals of @entity5 immunotherapy is to generate immune cells with potent anti- @entity5 activity through in vitro techniques using peripheral blood collected from @entity1 . However, @entity5 @entity1 generally have poor immunological function. Thus using @entity1 T cells, which have reduced in vitro proliferative capabilities and less @entity5 cell killing activity to generate @entity1199 -activated killer (LAK) cells, fails to achieve optimal clinical efficacy. @entity1199 ( @entity1199 ) is a potent activating cytokine for both T cells and natural killer cells. Thus, this study aimed to identify optimal donors for allogeneic LAK cell immunotherapy based on single nucleotide polymorphisms (SNP) in the @entity1199 and @entity2902 genes. @entity1199 and @entity2902 SNPs were analyzed using HRM- PCR. LAK cells were derived from peripheral blood mononuclear cells by culturing with @entity1199 . The frequency and @entity5 -killing activity of LAK cells in each group were analyzed by flow cytometry and @entity5 cell killing assays, respectively. Regarding polymorphisms at @entity1199 -330 ( @entity68111 ) @entity29102 , LAK cells from GG donors had significantly greater proliferation, @entity5 -killing activity, and @entity379 production than LAK cells from TT donors (P<0.05). Regarding polymorphisms at @entity2902 @entity66859 @entity4866 , LAK cell proliferation and @entity5 cell killing were significantly greater in LAK cells from AA donors than GG donors (P<0.05). These data suggest that either @entity1199 -330( @entity68111 )T/G GG donors or @entity2902 @entity66859 @entity4866 AA donors are excellent candidates for allogeneic LAK cell immunotherapy.

Impact of @entity1199 and XXXX SNPs on Proliferation and Tumor- killing Activity of @entity1199 -Activated Killer Cells from Healthy Chinese Blood Donors.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66859 :: ('rs2104286', 'SNP') :: ['rs2104286'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity4866 :: ('c|SUB|A||G', 'DNAMutation') :: ['A/G'] @entity68111 :: ('rs2069762', 'SNP') :: ['rs2069762'] @entity29102 :: ('c|SUB|T||G', 'DNAMutation') :: ['T/G'] @entity379 :: ('3458', 'Gene') :: ['IFN-y'] @entity2902 :: ('3559', 'Gene') :: ['IL-2R'] @entity1199 :: ('3558', 'Gene') :: ['IL-2', 'lymphokine', 'Interleukin-2', 'IL- 2']
@entity2902 :: (3559,Gene) :: ['IL-2R']
